HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
IPO Year: 2016
Exchange: NASDAQ
Website: hutch-med.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2025 | Buy → Hold | HSBC Securities | |
| 11/24/2023 | Hold → Buy | Deutsche Bank | |
| 5/4/2022 | Buy → Hold | Deutsche Bank | |
| 9/22/2021 | $46.00 | Buy → Neutral | Goldman |
| 8/3/2021 | $52.00 | Buy | Jefferies |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today jointly announce that the New Drug Application ("NDA") for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor ("TKI") has been accepted for review by the China National Medical Products Administration ("NMPA"). The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the effi
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation on Sunday, June 1, 2025, during the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, USA. SACHI is a Phas
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combination with osimertinib in patients with locally advanced or metastatic epidermal growth factor receptor ("EGFR") mutation-positive non-small cell lung cancer ("NSCLC") with MET amplific
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held May 15th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. May 15th Company Presentations Bavarian Nordic A/S ((Nasdaq Copenhagen: BAVA, OTC:BVNRY)Viomi Technology Co., Ltd. (NASDAQ:VIOT)Infineon Technologies AG ((Xetra: IFX, OTC:IFNNY)Clicks Group Ltd. ((JSE: CLS, OTC:CLCGY)First Paci
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois. Details of the presentations are as follows: Abstract titlePresenter / Lead authorPresentation detailsSPONSORED STUDIESTargeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitorsXianwen Yang, HUTCHMED, Shanghai, Ch
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification. This clinical trial is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and tolerability of savolitinib in treating gastric cancer or gastroesophageal junction ("GEJ") adenocarcinoma patients with MET amplification. Primary endpoint is objective response rate ("ORR") evaluated by the Independent Review Committee ("IRC") (RECIST 1.1). Secondary e
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory ("R/R") follicular lymphoma ("FL") with EZH2 mutation who have received at least two prior systemic therapies. This approval follows the priority review status by the National Medical Products Administration ("
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 13, 2025 ("AGM"). Consequently, both will cease to be Independent Non-executive Directors of the Company at the conclusion of the AGM. Upon their retirement, they will also step down from th
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors. She is an experienced board director and chair, with a healthcare and financial services background in investment banking, asset management, venture capital and compliance. The Board of HUTCHMED is of the vie
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:HCM; HKEX:13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call a
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that with effect from July 13, 2023: (i) Mr Lefei Sun, having left his position at General Atlantic, has resigned as Non-executive Director and member of the Technical Committee of HUTCHMED; and (ii) Ms Ling Yang, managing director of The Carlyle Group and co-head of Carlyle Asia Healthcare, has been appointed as Non-executive Director of HUTCHMED and will hold office until the next general meeting when she will stand for re-election. The Board of Directors of HUTCHMED (the "Bo
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023 ("AGM"). The Company today announces that the effective date of such appointments will be deferred until a later date to be announced by the Company. The Company also announces that Professor Mok Shu Kam,
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Solange Peters is appointed as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023. Professor Peters is a renowned scientist and educator who possesses expertise and extensive experience in oncology and immunology. The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Compan
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Karen Jean Ferrante has informed the Company that she would retire from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2023 ("AGM"), and that she would not be seeking re-election at the AGM so that she could devote more time to her personal engagements. Dr Ferrante will therefore cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon her retirement as a Director, Dr Ferrante will also cease to be chairman of the
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he will hold office until the next annual general meeting ("AGM") of HUTCHMED when he will stand for re-election. The Board of HUTCHMED considers that the appointment of Mr Sun will provide significant benefits to HUTCHMED in view of his experience in capital markets, M&A and business strategy. Aged 42, Mr Sun has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investmen